Skip to main content
OpenTrials
Completed

NCT Number: NCT04130555

Safety and Performance Evaluation of a Biological Matrix Used for Rectal Prolapse Repair by Ventral Rectopexy

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS Rectopexy membrane used in rectal prolapse repair by ventral rectopexy and to identify emerging risks in comparison to the clinical data related to other types of fixation material.

The present study will be a prospective multicentric non-randomized and non-controlled trial involving 55 patients followed for 24 months. The study will be conducted in France in 3 investigational centres.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rectal Prolapse Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Pelvic Organ Prolapse Prolapse Rectal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Estaing, Clermont-Ferrand, France

Loading trial locations.

About this study

The study will be prospective, multicentric, single-arm, observational (non-interventional) to evaluate the safety and performance of CELLIS Rectopexy used in rectal prolapse repair by ventral rectopexy.

All evaluations will be performed and products used according to the usual practice, without additional or unusual diagnostic, treatment and monitoring procedure.

The study will be conducted in France in 3 investigational centres including 55 patients scheduled for the repair of rectal prolapse.

Each patient will participate in one assessment period including a screening visit, followed by the day of surgical procedure and a hospitalization period. Patients will return for ambulatory visits at Day 30 (+/- 7 days), Month 6 (+/- 2 weeks), Month 12 (+/- 2 weeks) and Month 24 (+/-2 weeks).

The surgical technique used to repair rectal prolapse will be either Laparoscopic Ventral Rectopexy (LVR) or a robotic assisted rectopexy with the use of the da Vinci Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged ≥18 years,
  • Patient with an indication of rectal prolapse repair by ventral rectopexy (external and internal rectal prolapse),
  • Patient being informed of its participation to the study and of the follow-up visits, and having no objection to the clinical data collection and medical file access,
  • Patient being informed of the porcine origin of the device in advance of the procedure.

Exclusion criteria

  • Patient with known hypersensitivity to porcine materials,
  • Patient with an existing infection not appropriately treated,
  • Patient who are pregnant,
  • Patient having refused to participate to the study,
  • Patient refusing to come back to the follow-up visits.

Treatment and study plan

CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)

Device

Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy

Primary outcomes

  1. Rate of adverse events including reoperation and removal of the mesh

    Time frame: From the surgical procedure through the entire 24-month follow-up period

    Percentage

Secondary outcomes

  1. Rate of structural defect recurrence based on rectal examination with/without adjunctive investigations as clinically indicated

    Time frame: Throughout the study until end of the 24-month follow-up period

    Percentage

  2. Rate of structural defect recurrence requiring reoperation

    Time frame: Throughout the study until end of the 24-month follow-up period

    Percentage

  3. Symptoms evolution: presence or absence of symptoms (constipation, fecal incontinence, bloody and/or mucous rectal discharge (soiling), unsatisfactory sexual activity, pain)

    Time frame: At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits

    Described at each visit and compared to baseline

  4. Symptoms severity scored by a visual analog scale (0-10; 0 corresponding to no impact on life and 10 corresponding to extreme, incapacitating impact)

    Time frame: At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits

    Described at each visit and compared to baseline

  5. Rate of symptoms recurrence

    Time frame: Throughout the study until end of the 24-month follow-up period

    Percentage

  6. Severity of disease by the use of the Cleveland Clinic Incontinence Score (CCIS)

    Time frame: At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits

    Change from screening of total score at each follow-up visit. This scoring system cross-tabulates frequencies and different anal incontinence presentations (Gas/Liquid/Solid/Pad use/Need for lifestyle alterations) and sums the returned score to a total of 0-20 (where 0 = perfect continence and 20 = complete incontinence).

  7. Severity of disease by the use of the Obstructed Defecation Score (ODS)

    Time frame: At baseline and at 30-day, 6-month, 12-month and 24-month follow-up visits

    Change from screening of total score at each follow-up visit. The ODS score is the sum of all points, with a minimum of 0 point and a maximum possible of 31 points with higher scores meaning worse outcome.

  8. Quality of life by the use of the Short Form (36) Health Survey (SF-36) questionnaire

    Time frame: At baseline and at 24-month

    Change from screening of each domain score and total score at 24-month. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 with lower scores = more disability, and higher scores = less disability

  9. Description of device deficiency: inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance. Device deficiencies include malfunctions, use errors, and inadequate labelling.

    Time frame: During the surgical procedure

    Summarized and listed

Sponsors and collaborators

Lead sponsor

Meccellis Biotech

Industry

Registry information

Official study title

Observational Prospective Study of a Non-cross-linked Porcine Acellular Dermal Matrix in Ventral Mesh Rectopexy

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Oct 17, 2019
Registry last updated
Oct 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.